What does this research mean for the field?

Q: What does this research mean for the field?

DMP 728, a novel platelet GPIIb/IIIa antagonist, demonstrates dose-dependent oral antiplatelet and antithrombotic efficacy in canine models of arterial thrombosis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 1, 1996Circulation

Oral Antiplatelet, Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Antagonist

View Full Paper

Ask AI

Bookmark

Why the study?

Does DMP 728 inhibit platelet aggregation and prevent thrombosis in canine arterial thrombosis models?

Population

Conscious and anesthetized mongrel dogs in various arterial thrombosis models

Design

Preclinical

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill WDWilliam F. DeGradoUniversity of the Sciences DMDun-Xu MuWilmington University

Discussion

Member takes

Implication

Supports oral GPIIb/IIIa antagonism in canine thrombosis; leaves open human efficacy trials.

Structured PICO

Does DMP 728 inhibit platelet aggregation and prevent thrombosis in canine arterial thrombosis models?

Population

Conscious and anesthetized mongrel dogs in various arterial thrombosis models (coronary artery Folts' model, electrolytically induced carotid artery thrombosis model)

Intervention

DMP 728 0.02 to 1.0 mg/kg PO and 0.01 to 1.0 mg/kg IV

Outcome

Inhibition of ex vivo platelet aggregation induced by ADP, prolongation of template bleeding time, and prevention of primary thrombosissurrogate

DMP 728 demonstrates potent oral antiplatelet and antithrombotic efficacy in canine models of arterial thrombosis.

Cite This Study

Mousa et al. (1996) studied this question.

synapsesocial.com/papers/6a1bc2dd69a4af5b15a8f3c2 https://doi.org/10.1161/01.cir.93.3.537

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark